ANDA 62365, held by Fresenius Kabi USA. Chloramphenicol Sodium Succinate.
As of Nov 16, 2026, ANDA 62365 (Chloramphenicol Sodium Succinate), held by Fresenius Kabi USA, was first approved by FDA on Aug 25, 1982, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Chloramphenicol Sodium SuccinateEQ 1GM BASE/VIAL · injectable;injection | Chloramphenicol Sodium Succinate | Discontinued |
| Aug 1, 2016 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 1, 2016 | Supplement 20Labeling · Standard review | Approved | None posted |
| Nov 10, 2014 | Supplement 19Manufacturing | Approved | None posted |
| Dec 5, 2002 | Supplement 12Manufacturing | Approved | None posted |
| Jul 15, 2002 | Supplement 11Manufacturing | Approved | None posted |
| Apr 8, 1993 | Supplement 9Labeling | Approved | None posted |
| Dec 15, 1992 | Supplement 8Labeling | Approved | None posted |
| Sep 10, 1992 | Supplement 7Labeling | Approved | None posted |
| Nov 23, 1988 | Supplement 6Manufacturing | Approved | None posted |
| Aug 25, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters